Short answer · Medically reviewed summary · Last updated: 2026-04-07
Lymphangioleiomyomatosis (LAM) is classified under the ICD-10 code J84.81 and the ICD-9 code 516.8. These diagnostic codes are essential for healthcare documentation, insurance billing, and tracking the clinical management of this rare, progressive cystic lung disease. What is the clinical significance of the Lymphangioleiomyomatosis ICD codes? The assignment of specific diagnostic codes, such as the ICD-10 code J84.81 for Lymphangioleiomyomatosis, allows clinicians and researchers to accurately identify and track patient outcomes.
ICD10 code of Lymphangioleiomyomatosis and ICD9 code
ICD-10 and ICD-9 codes for Lymphangioleiomyomatosis, with classification details for clinicians, coders and patients.
Lymphangioleiomyomatosis (LAM) is classified under the ICD-10 code J84.81 and the ICD-9 code 516.8. These diagnostic codes are essential for healthcare documentation, insurance billing, and tracking the clinical management of this rare, progressive cystic lung disease.
What is the clinical significance of the Lymphangioleiomyomatosis ICD codes?
The assignment of specific diagnostic codes, such as the ICD-10 code J84.81 for Lymphangioleiomyomatosis, allows clinicians and researchers to accurately identify and track patient outcomes. Because Lymphangioleiomyomatosis is a rare condition that primarily affects women of childbearing age, having standardized coding is vital for ensuring that patients receive appropriate insurance coverage for specialized treatments, such as mTOR inhibitors. Accurate coding also assists medical registries, including the DiseaseMaps.org community where 9 members have shared their experiences, to aggregate data and better understand the prevalence and progression of the disease.
What exactly is Lymphangioleiomyomatosis?
Lymphangioleiomyomatosis is a rare, multisystem disorder characterized by the abnormal, tumor-like growth of smooth muscle cells (LAM cells) in the lungs, airways, and blood vessels. These cells destroy lung tissue by forming small, air-filled cysts, which gradually impede the body's ability to exchange oxygen. While the disease is primarily pulmonary, it can also manifest as angiomyolipomas (benign kidney tumors) or lymphangioleiomyomas (fluid-filled masses in the abdomen or chest). Understanding that Lymphangioleiomyomatosis is a systemic disease helps patients navigate the multidisciplinary care required for effective management.
How is the diagnosis of Lymphangioleiomyomatosis confirmed?
Diagnosis typically involves a combination of high-resolution computed tomography (HRCT) of the chest and, in some cases, blood tests or tissue biopsies. Physicians look for specific patterns of thin-walled, diffuse cystic changes in the lung parenchyma. The diagnostic process often includes:
- HRCT Imaging: Identifying characteristic cystic lung disease.
- Serum VEGF-D Testing: Elevated levels of vascular endothelial growth factor-D (VEGF-D) are a highly specific biomarker for Lymphangioleiomyomatosis.
- Pulmonary Function Tests (PFTs): Measuring airflow obstruction and gas exchange efficiency.
- Clinical History: Assessing for history of pneumothorax (collapsed lung) or chylous effusions.
What is the emotional impact of living with a rare diagnosis?
Receiving a diagnosis of Lymphangioleiomyomatosis can be an isolating and overwhelming experience. From a psychological perspective, the uncertainty of a rare disease progression often triggers significant anxiety. It is important for patients to recognize that they are not alone; connecting with the 9 members of the DiseaseMaps.org community or participating in specialized patient advocacy groups can provide a sense of agency and shared understanding. Managing the emotional burden is just as critical as managing the physiological symptoms of Lymphangioleiomyomatosis.
Next steps
- Consult with a pulmonologist or a specialized center of excellence familiar with the management of rare cystic lung diseases.
- Request a baseline VEGF-D blood test if it has not already been performed.
- Connect with the DiseaseMaps.org community to share experiences and find peer support.
- Register with the LAM Foundation to access educational resources and information on clinical trials.
- Monitor lung function regularly through scheduled PFTs as recommended by your specialist.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
References
- The LAM Foundation (thelamfoundation.org)
- NIH Genetic and Rare Diseases Information Center (GARD): Lymphangioleiomyomatosis
- Orphanet: Rare Disease Database (ORPHA: 2356)
- OMIM (Online Mendelian Inheritance in Man): #606690
